TIDMAMS
RNS Number : 1616H
Advanced Medical Solutions Grp PLC
02 August 2021
2 August 2021
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Directorate Change
Douglas Le Fort Appointed as Independent Non-Executive
Director
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the surgical and advanced woundcare specialist company , is pleased
to announce that, as the next step in its communicated plan to
refresh the Non-Executive Directors on the Board, Douglas Le Fort
has today been appointed as an Independent Non-Executive
Director.
Douglas is a seasoned veteran in the medical and life science
industry, with more than 20 years of senior executive leadership.
He has expertise in business strategy, including commercial
business execution, operational management and M&A. He is
currently an Operating Partner for Revival Healthcare Capital
Partners, an investor in medical device and diagnostics businesses,
as well as a Non-Executive Director at Trio Healthcare, a
manufacturer of ostomy products. Most recently, he was CEO of
MedTrade Products, a woundcare products business and prior to that
served in various senior executive roles at ConvaTec Group plc,
including five years on the Executive Committee for the Group. At
ConvaTec he was Senior Vice President for Corporate Development,
and prior to that Vice President and General Manager with P&L
responsibility for the global Ostomy business. He has an MBA from
Henley Management College and is a Chartered Management
Accountant.
Peter Allen, Chairman of AMS, said : "I am very pleased to
welcome Douglas to the Board of AMS, who brings with him
significant commercial experience, particularly during his time at
ConvaTec, as well as sector expertise. He will be an extremely
valuable addition to our Board as AMS looks to grow."
Douglas Le Fort commented : "I have been watching AMS's progress
closely during my career and am very excited to be joining the team
at such a high-quality Company. Alongside the rest of the Board, my
focus will be on supporting AMS's growth strategy and providing
strategic advice as the business builds on its position in the UK
and internationally."
Douglas will immediately join the Audit, Nomination and
Remuneration Committees. The composition of each of the Board
Committees from 2 August 2021 is therefore confirmed as
follows:
Board Committee Membership
Audit Committee Grahame Cook (Chairman)
Penny Freer
Douglas Le Fort
------------------------
Nomination Committee Peter Allen (Chairman)
Grahame Cook
Penny Freer
Douglas Le Fort
Chris Meredith
------------------------
Remuneration Committee Penny Freer (Chairman)
Peter Allen
Grahame Cook
Douglas Le Fort
------------------------
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Douglas William Frederick Le Fort (age 55) holds or has held
directorships and partnerships in the five years preceding his
appointment at AMS as follows:
Current Directorships Previous Directorships
Trio Healthcare Holdings Ltd MedTrade Products Ltd
-----------------------
Wolfpack Consulting Ltd
-----------------------
Mr Le Fort was a Director of Freehand Surgical plc in 2010 when
it, and its subsidiary Prosurgics Limited, was put into
administration. Mr Le Fort had previously been a Director of
Prosurgics Limited which had been acquired by Freehand Surgical
plc. Freehand Surgical plc was subsequently acquired by Freehand
2010 Limited by way of a pre-pack sale. Mr Le Fort was a Director
of Freehand 2010 Limited at the time of it acquiring Freehand
Surgical plc.
No further information in connection with his appointment is
required to be disclosed under Schedule Two, paragraph (g) of the
AIM Rules for Companies.
-End -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Matthew AMS@consilium-comms.com
Cole
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Patrick Robb / Gary Clarence
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical and woundcare markets, focused on quality outcomes for
patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, and
internal fixation devices, which it markets under its brands
LiquiBand(R) , RESORBA(R) , and LiquiBandFix8(R) . AMS also
supplies wound care dressings such as silver alginates, alginates
and foams through its ActivHeal(R) brand as well as under white
label. In 2019, the Group made two acquisitions: Sealantis, an
Israeli medical device company with a patent-protected sealant
technology platform; and Biomatlante, an established developer and
manufacturer of innovative surgical biomaterial technologies based
in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a
leading coater and converter of materials predominately for
woundcare and bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, Israel,
the Netherlands, and the Czech Republic, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Germany, France and Israel. Established in 1991, the Group
has more than 700 employees. For more information, please see
www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUPUGWRUPGPUG
(END) Dow Jones Newswires
August 02, 2021 02:00 ET (06:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Mar 2023 to Mar 2024